Biotechnology & Biotechnological Equipment (Dec 2024)

Implementation of DPYD testing in Bulgarian patients with cancer

  • Nelly Miteva-Marcheva,
  • Hristo Ivanov,
  • Elena Bangieva-Ivanova,
  • Nikola Boyanov,
  • Vili Stoyanova

DOI
https://doi.org/10.1080/13102818.2024.2386073
Journal volume & issue
Vol. 38, no. 1

Abstract

Read online

Precision medicine has revolutionized cancer treatment, tailoring interventions based on individual genetic variations. Dihydropyrimidine dehydrogenase gene (DPYD) testing plays a crucial role in predicting severe fluoropyrimidine-related toxicities. This paper explores the broader landscape of DPYD testing in the realm of precision medicine. Our study encompassed 86 cancer patients who underwent DPYD testing. Utilizing a comprehensive approach, we employed a questionnaire comprising 10 questions, distributed to 31 oncologists. The analysis revealed no statistically significant difference in allele frequency between our tested individuals and the global database. While our results affirmed the global relevance of DPYD testing, the study highlights hurdles faced by oncologists. The main hindrances that impede the widespread adoption of DPYD testing encompass limited knowledge, absence of standardized protocols in Bulgaria, challenges in result interpretation and financial constraints. Overcoming these barriers is paramount to ensuring equitable access to DPYD testing, ultimately optimizing cancer treatment outcomes in the era of precision medicine. Efforts must be directed toward establishing funding mechanisms and raising awareness to facilitate seamless integration of DPYD testing into routine oncological practice.

Keywords